Cargando…

Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials

BACKGROUND: Giardia duodenalis is the most common intestinal pathogenic protozoan infection reported in humans. Both in vitro studies and 4 separate, sequential, comparative clinical trials conducted by our group in Cuba demonstrated mebendazole activity against G. duodenalis infection in both child...

Descripción completa

Detalles Bibliográficos
Autores principales: Cañete, Roberto, Brito, Katia, Brito, Inara, Semper, Abel, Gonzalez, Maria Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370949/
https://www.ncbi.nlm.nih.gov/pubmed/30792825
http://dx.doi.org/10.1016/j.curtheres.2018.11.002
_version_ 1783394466152841216
author Cañete, Roberto
Brito, Katia
Brito, Inara
Semper, Abel
Gonzalez, Maria Elena
author_facet Cañete, Roberto
Brito, Katia
Brito, Inara
Semper, Abel
Gonzalez, Maria Elena
author_sort Cañete, Roberto
collection PubMed
description BACKGROUND: Giardia duodenalis is the most common intestinal pathogenic protozoan infection reported in humans. Both in vitro studies and 4 separate, sequential, comparative clinical trials conducted by our group in Cuba demonstrated mebendazole activity against G. duodenalis infection in both children and adults. OBJECTIVE: The 2 additional, prospective, open-label, Phase IV follow-up studies reported here were performed to further assess the effectiveness and safety profile of mebendazole in the outpatient treatment of G. duodenalis infection. METHODS: Assenting children (n = 522) whose guardians gave permission and consenting adults (n = 423) diagnosed with G. duodenalis infection were given mebendazole (200 mg 3 times daily for 3 days). Medical histories and stool samples were obtained and physical/laboratory examinations were performed pretreatment then repeated on days 3, 5, and 7 after treatment completion. The evaluation of efficacy (ie, cure) was based on parasitologic response to therapy. Participants were considered cured, if no Giardia trophozoites or cysts were found in any of the 3 posttreatment fecal specimens evaluated by direct wet mounts and/or after Ritchie concentration techniques. RESULTS: No participant refused to be enrolled and all returned for follow-up examinations. At the end of the treatment, stool samples were negative in 450 out of 522 children (86.2%) and 392 of 423 adults (92.7%). Treatment was well tolerated. In adults, the only adverse effect reported was abdominal pain (6.2%). Side effects reported in children included abdominal pain (5.6%), nausea (2.9%), and vomiting (2.3%). Reported side effects were all mild, transient, and self-limited and did not require discontinuation of treatment or additional medication. CONCLUSIONS: Mebendazole may be an effective alternative treatment of G. duodenalis infections in both children and adults.
format Online
Article
Text
id pubmed-6370949
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-63709492019-02-21 Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials Cañete, Roberto Brito, Katia Brito, Inara Semper, Abel Gonzalez, Maria Elena Curr Ther Res Clin Exp Original Research BACKGROUND: Giardia duodenalis is the most common intestinal pathogenic protozoan infection reported in humans. Both in vitro studies and 4 separate, sequential, comparative clinical trials conducted by our group in Cuba demonstrated mebendazole activity against G. duodenalis infection in both children and adults. OBJECTIVE: The 2 additional, prospective, open-label, Phase IV follow-up studies reported here were performed to further assess the effectiveness and safety profile of mebendazole in the outpatient treatment of G. duodenalis infection. METHODS: Assenting children (n = 522) whose guardians gave permission and consenting adults (n = 423) diagnosed with G. duodenalis infection were given mebendazole (200 mg 3 times daily for 3 days). Medical histories and stool samples were obtained and physical/laboratory examinations were performed pretreatment then repeated on days 3, 5, and 7 after treatment completion. The evaluation of efficacy (ie, cure) was based on parasitologic response to therapy. Participants were considered cured, if no Giardia trophozoites or cysts were found in any of the 3 posttreatment fecal specimens evaluated by direct wet mounts and/or after Ritchie concentration techniques. RESULTS: No participant refused to be enrolled and all returned for follow-up examinations. At the end of the treatment, stool samples were negative in 450 out of 522 children (86.2%) and 392 of 423 adults (92.7%). Treatment was well tolerated. In adults, the only adverse effect reported was abdominal pain (6.2%). Side effects reported in children included abdominal pain (5.6%), nausea (2.9%), and vomiting (2.3%). Reported side effects were all mild, transient, and self-limited and did not require discontinuation of treatment or additional medication. CONCLUSIONS: Mebendazole may be an effective alternative treatment of G. duodenalis infections in both children and adults. Elsevier 2018-11-30 /pmc/articles/PMC6370949/ /pubmed/30792825 http://dx.doi.org/10.1016/j.curtheres.2018.11.002 Text en © 2019 The Authors. Published by Elsevier Inc. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Original Research
Cañete, Roberto
Brito, Katia
Brito, Inara
Semper, Abel
Gonzalez, Maria Elena
Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials
title Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials
title_full Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials
title_fullStr Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials
title_full_unstemmed Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials
title_short Effectiveness and Tolerability of 3-Day Mebendazole Treatment of Giardia duodenalis Infection in Adults and Children: Two Prospective, Open-Label Phase IV Trials
title_sort effectiveness and tolerability of 3-day mebendazole treatment of giardia duodenalis infection in adults and children: two prospective, open-label phase iv trials
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6370949/
https://www.ncbi.nlm.nih.gov/pubmed/30792825
http://dx.doi.org/10.1016/j.curtheres.2018.11.002
work_keys_str_mv AT caneteroberto effectivenessandtolerabilityof3daymebendazoletreatmentofgiardiaduodenalisinfectioninadultsandchildrentwoprospectiveopenlabelphaseivtrials
AT britokatia effectivenessandtolerabilityof3daymebendazoletreatmentofgiardiaduodenalisinfectioninadultsandchildrentwoprospectiveopenlabelphaseivtrials
AT britoinara effectivenessandtolerabilityof3daymebendazoletreatmentofgiardiaduodenalisinfectioninadultsandchildrentwoprospectiveopenlabelphaseivtrials
AT semperabel effectivenessandtolerabilityof3daymebendazoletreatmentofgiardiaduodenalisinfectioninadultsandchildrentwoprospectiveopenlabelphaseivtrials
AT gonzalezmariaelena effectivenessandtolerabilityof3daymebendazoletreatmentofgiardiaduodenalisinfectioninadultsandchildrentwoprospectiveopenlabelphaseivtrials